Evidence map›Paper›PMID 37888134›Full record

ArticleJournal of personalized medicine2023

Assessing the Potential Risks of Digital Therapeutics (DTX): The DTX Risk Assessment Canvas.

Kerstin Denecke, Richard May, Elia Gabarron, Guillermo H Lopez-Campos

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Diving into the Regulatory Landscape of Digital Therapeutics.Therapeutic innovation & regulatory science · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Co-Creation in the Development of Digital Therapeutics: A Narrative Review.International journal of environmental research and public health · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 4 countries.

Kerstin DeneckeDepartment Engineering and Computer Science, Institute Patient-Centered Digital Health, Bern University of Applied Sciences, 3012 Bern, Switzerland.ORCID 0000-0001-6691-396X
Richard MayDepartment of Automation and Computer Science, Harz University of Applied Sciences, 38855 Wernigerode, Germany.ORCID 0000-0001-7186-404X
Elia GabarronNorwegian Centre for E-Health Research, University Hospital of North Norway, 9019 Tromsø, Norway.
Guillermo H Lopez-CamposWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast BT9 7BL, UK.
Bern University of Applied Sciences · CHHarz University of Applied Sciences · DEQueen's University Belfast · GBUniversity Hospital of North Norway · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

motivationDigital therapeutics (DTX), i.e., health interventions that are provided through digital means, are increasingly available for use; in some countries, physicians can even prescribe selected DTX following a reimbursement by health insurances. This results in an increasing need for methodologies to consider and monitor DTX's negative consequences, their risks to patient safety, and possible adverse events. However, it is completely unknown which aspects should be subject to surveillance given the missing experiences with the tools and their negative impacts.

objectiveOur aim is to develop a tool-the DTX Risk Assessment Canvas-that enables researchers, developers, and practitioners to reflect on the negative consequences of DTX in a participatory process.

methodTaking the well-established business model canvas as a starting point, we identified relevant aspects to be considered in a risk assessment of a DTX. The aspects or building blocks of the canvas were constructed in a two-way process: first, we defined the aspects relevant for discussing and reflecting on how a DTX might bring negative consequences and risks for its users by considering ISO/TS 82304-2, the scientific literature, and by reviewing existing DTX and their listed adverse effects. The resulting aspects were grouped into thematic blocks and the canvas was created. Second, six experts in health informatics and mental health provided feedback and tested the understandability of the initial canvas by individually applying it to a DTX of their choice. Based on their feedback, the canvas was modified.

resultsThe DTX Risk Assessment Canvas is organized into 15 thematic blocks which are in turn grouped into three thematic groups considering the DTX itself, the users of the DTX, and the effects of the DTX. For each thematic block, questions have been formulated to guide the user of the canvas in reflecting on the single aspects.

Indexed as

adverse eventdigital therapeuticspatient safetysurveillance

Identifiers

PMID37888134
PMCPMC10608744
OpenAlexW4387880627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.